UBS Initiates Coverage On Viking Therapeutics with Buy Rating, Announces Price Target of $94

Benzinga · 1d ago
UBS analyst Joon Lee initiates coverage on Viking Therapeutics (NASDAQ:VKTX) with a Buy rating and announces Price Target of $94.